• Vaccine Name: Pfs25-IMX313/Matrix-M
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: protein-nanoparticle vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: Pfs25: post-fertilization antigen, three potential N-linked glycosylation sites (112, 165 and 187) mutated. Involved in ookinete formation, survival in the mosquito midgut, and a possible role in parasite traversal of the mid-gut epithelium. (Mulamba et al., 2022)
• Pfs25 from P. falciparum 3D7 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Pfs25 antigen is genetically fused to the IMX313 oligomerization domain (Mulamba et al., 2022)
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0005206
  • Description: A potent saponinbased adjuvant, comprising partially purifed extracts of the bark of the Quillaja saponaria Molina tree, phosphatidylcholine and cholesterol. Enhance immune responses (Mulamba et al., 2022)
• Immunization Route: Intramuscular injection (i.m.)
• Description: **Mechanism: Human get vaccinated --> Human produce antibodies --> mosquitoes take up antibodies --> reduce parasite fertilization in mosquitoes (Mulamba et al., 2022)

Human Response

• Host Strain: Semi-immune healthy adults from Bagamoyo district in Tanzania
• Vaccination Protocol: Phase I trial, not started.
  A two-years enrollment schedule has been designed, with one group of volunteers receiving immunization at months; zero, one and three, while another group shall receive immunization at months; zero, one and seven.
  Enrollment of volunteers will follow a strict staggered approach, with one of group of adults receiving a low dose of the vaccine followed by another adults’ group receiving a high dose of the vaccine in six-weeks interval.(Mulamba et al., 2022)